126 related articles for article (PubMed ID: 38882208)
21. Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
Cheng SMS; Mok CKP; Li JKC; Chan KKP; Luk KS; Lee BHW; Gu H; Chan KCK; Tsang LCH; Yiu KYS; Ling KKC; Tang YS; Luk LLH; Yu JKM; Pekosz A; Webby RJ; Cowling BJ; Hui DSC; Peiris M
Virol J; 2024 Mar; 21(1):70. PubMed ID: 38515117
[TBL] [Abstract][Full Text] [Related]
22. The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection.
Tian D; Nie W; Sun Y; Ye Q
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298564
[TBL] [Abstract][Full Text] [Related]
23. Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals.
Kuzel TG; Fu J; Anderson M; Stec M; Boler M; Behun D; Gosha A; Cloherty G; Landay A; Moy J
Vaccine; 2023 Jan; 41(4):879-882. PubMed ID: 36572601
[TBL] [Abstract][Full Text] [Related]
24. Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5.
Tamura T; Yamasoba D; Oda Y; Ito J; Kamasaki T; Nao N; Hashimoto R; Fujioka Y; Suzuki R; Wang L; Ito H; Kashima Y; Kimura I; Kishimoto M; Tsuda M; Sawa H; Yoshimatsu K; Yamamoto Y; Nagamoto T; Kanamune J; Suzuki Y; Ohba Y; ; Yokota I; Matsuno K; Takayama K; Tanaka S; Sato K; Fukuhara T
Commun Biol; 2023 Jul; 6(1):772. PubMed ID: 37488344
[TBL] [Abstract][Full Text] [Related]
25. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination
Wang H; Xue Q; Zhang H; Yuan G; Wang X; Sheng K; Li C; Cai J; Sun Y; Zhao J; Lu J; Fang S; Yang Y; Zhang Y; Huang Y; Wang J; Xu JH; Jiang MX; Wang X; Shen L; Liu Y; Liu Q; Zhang Q; Wang S; Wang P; Qiu C; Ai J; Zhang W
Emerg Microbes Infect; 2023 Dec; 12(2):2249121. PubMed ID: 37668156
[TBL] [Abstract][Full Text] [Related]
26. Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants.
Faraone JN; Qu P; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Gumina RJ; Liu SL
Cell Rep Med; 2023 May; 4(5):101049. PubMed ID: 37148877
[TBL] [Abstract][Full Text] [Related]
27. Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization.
Feikin DR; Higdon MM; Andrews N; Collie S; Deloria Knoll M; Kwong JC; Link-Gelles R; Pilishvili T; Patel MK
Vaccine; 2023 Mar; 41(14):2329-2338. PubMed ID: 36797097
[TBL] [Abstract][Full Text] [Related]
28. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Boland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; ; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
bioRxiv; 2024 Feb; ():. PubMed ID: 38045308
[TBL] [Abstract][Full Text] [Related]
29. Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBD.
Liu Z; Zhou J; Wang W; Zhang G; Xing L; Zhang K; Wang Y; Xu W; Wang Q; Man Q; Wang Q; Ying T; Zhu Y; Jiang S; Lu L
Cell Rep Med; 2024 Mar; 5(3):101445. PubMed ID: 38428429
[TBL] [Abstract][Full Text] [Related]
30. A cross-sectional study of SARS-CoV-2 antibodies among healthcare workers in a tertiary care hospital in Taiwan: implications for protection against the Omicron variants.
Chen CH; Chao DY; Kor CT; Kuo SF; Lin JS; Lai HW; Liu YT; Lin CH; Chen MK
BMC Infect Dis; 2024 May; 24(1):529. PubMed ID: 38802771
[TBL] [Abstract][Full Text] [Related]
31. Antibody evasion associated with the RBD significant mutations in several emerging SARS-CoV-2 variants and its subvariants.
Bhattacharya M; Chatterjee S; Lee SS; Dhama K; Chakraborty C
Drug Resist Updat; 2023 Nov; 71():101008. PubMed ID: 37757651
[TBL] [Abstract][Full Text] [Related]
32. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
[TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1.
Wang Q; Guo Y; Schwanz LT; Mellis IA; Sun Y; Qu Y; Urtecho G; Valdez R; Stoneman E; Gordon A; Wang HH; Ho DD; Liu L
Emerg Microbes Infect; 2024 Dec; 13(1):2359004. PubMed ID: 38779718
[TBL] [Abstract][Full Text] [Related]
34. Unique mutations in SARS-CoV-2 Omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion.
Hossain A; Akter S; Rashid AA; Khair S; Alam ASMRU
Microb Pathog; 2022 Sep; 170():105699. PubMed ID: 35944840
[TBL] [Abstract][Full Text] [Related]
35. Long-term variations and potency of neutralizing antibodies against Omicron subvariants after CoronaVac-inactivated booster: A 7-month follow-up study.
Li X; Yin Y; Cui Q; Huang W; Zou Q; Shen T
J Med Virol; 2023 Jan; 95(1):e28279. PubMed ID: 36329634
[TBL] [Abstract][Full Text] [Related]
36. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Bolland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
Nat Commun; 2024 Mar; 15(1):2254. PubMed ID: 38480689
[TBL] [Abstract][Full Text] [Related]
37. Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants.
Qu P; Evans JP; Kurhade C; Zeng C; Zheng YM; Xu K; Shi PY; Xie X; Liu SL
mBio; 2023 Feb; 14(1):e0317622. PubMed ID: 36625591
[TBL] [Abstract][Full Text] [Related]
38. SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals.
Emmelot ME; Vos M; Boer MC; Rots NY; van Els CACM; Kaaijk P
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680141
[TBL] [Abstract][Full Text] [Related]
39. Emerging Omicron subvariants evade neutralizing immunity elicited by vaccine or BA.1/BA.2 infection.
Chen Z; Li J; Zheng J; Jin Y; Zhang Y; Tang F; Li J; Cheng H; Jiang L; Wen H; Hong C; Zeng X; Huang S; Lu B; Li L; Wang Z
J Med Virol; 2023 Feb; 95(2):e28539. PubMed ID: 36719034
[TBL] [Abstract][Full Text] [Related]
40. Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics.
Pérez-Vargas J; Shapira T; Olmstead AD; Villanueva I; Thompson CAH; Ennis S; Gao G; De Guzman J; Williams DE; Wang M; Chin A; Bautista-Sánchez D; Agafitei O; Levett P; Xie X; Nuzzo G; Freire VF; Quintana-Bulla JI; Bernardi DI; Gubiani JR; Suthiphasilp V; Raksat A; Meesakul P; Polbuppha I; Cheenpracha S; Jaidee W; Kanokmedhakul K; Yenjai C; Chaiyosang B; Teles HL; Manzo E; Fontana A; Leduc R; Boudreault PL; Berlinck RGS; Laphookhieo S; Kanokmedhakul S; Tietjen I; Cherkasov A; Krajden M; Nabi IR; Niikura M; Shi PY; Andersen RJ; Jean F
Antiviral Res; 2023 Jan; 209():105484. PubMed ID: 36503013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
